Rate My Professor David Goode

Dr. David Goode is a Senior Lecturer in the Department of Biochemistry and Molecular Biology and head of the Cancer Bioinformatics and Tumour Evolution group at Monash University's Monash Biomedicine Discovery Institute. He completed his PhD in Genetics at Stanford University between 2005 and 2010, after serving as an undergraduate research assistant at the University of British Columbia. Before his current role, Goode worked for several years at the Peter MacCallum Cancer Centre. His research employs bioinformatics, molecular evolution, and population genetics to analyze large cancer genomics datasets, investigating how tumors evolve, adapt, develop phenotypic plasticity, and acquire resistance to therapies. Particular emphases include gene regulation changes and microenvironmental influences in prostate cancer, brain cancer (glioma), and other solid tumors. The group utilizes evolutionary perspectives on cancer omics data—including genomes, RNA sequencing, and spatial transcriptomics—from patient samples and laboratory models, increasingly integrating machine learning and computational modeling for translational insights.

With 59 peer-reviewed publications and an h-index of 24 (Web of Science), Goode's contributions appear in prestigious journals such as Science, Nature Genetics, The Lancet Oncology, PNAS, Genome Biology, and eLife. Notable works include "Identifying a high fraction of the human genome to be under selective constraint using GERP++" (PLoS Computational Biology, 2010; 2151 citations), "Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors" (PNAS, 2017; 242 citations), "Monogenic and polygenic determinants of sarcoma risk: an international genetic study" (The Lancet Oncology, 2016; 255 citations), and the recent "Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins" (Genome Biology, 2024). He has been awarded the Victorian Cancer Agency Mid-Career Fellowship (2018-2023) and the NHMRC Peter Doherty Early Career Fellowship (2013-2016). Goode leads projects on therapy resistance in prostate cancer, tumor immune microenvironments in brain cancer, ancestry-specific cancer differences, and tumor evolutionary predictions. He collaborates with the Monash Prostate Cancer Research Program, Brain Cancer Centre at WEHI, and clinical oncology groups, advancing precision medicine in oncology.